GeoVax Labs, Inc.: Form 10-Q for the period ended Mar 31, 2025
Filed with the SEC on May 1, 2025 and accepted by EDGAR at May 1, 2025, 16:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-01-01 to 2025-03-31 | $1.6m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Research and development | 3 months2025-01-01 to 2025-03-31 | $5.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-01-01 to 2025-03-31 | −$5.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-01-01 to 2025-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-01-01 to 2025-03-31 | −$5.4m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2025-01-01 to 2025-03-31 | −$0.45 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months2025-01-01 to 2025-03-31 | −$6.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2025-01-01 to 2025-03-31 | $16.9k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-03-31 | $7.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-03-31 | $10.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-03-31 | $10.8m | us-gaap:Assets |
| Current liabilities | At period end2025-03-31 | $2.9m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2025-03-31 | $7.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-25-014083. Last ingested by Listed: Oct 27, 2026, 13:01 ET. Listed shows no prices and gives no investment advice.